Eligibility turns on four tests: what kind of insurance you hold, what the prescription is written for, what your household earns, and whether your enrollment is still current. Different programs weigh those tests differently, and a card and an assistance program can reach opposite conclusions about the same person.
Two things called assistance that are not the same
The word covers two structures with almost nothing in common except the manufacturer behind them.
A copay savings card is a commercial marketing instrument. It presumes an active commercial plan, an accepted pharmacy claim, and a remaining patient share. The card pays down part of that share at the counter, often up to an annual maximum. Nothing about it is charitable, and income has no bearing on it.
A patient assistance program is a supply program. It exists for people who cannot buy the drug at all, generally because they are uninsured or their income sits under a stated ceiling. It runs on an application rather than a card, needs a prescriber to sign, needs proof of income, and supplies product through a designated program pharmacy rather than a retail counter.
Reading a card decline as an assistance decline is the most common wrong turn in this whole process. They are separate applications, judged on separate facts.
Test one: the type of insurance you hold
This test disqualifies more people than income does. Coverage through Medicare, Medicaid, TRICARE, the VA, or any other federal health program generally makes a patient ineligible for a commercial copay card. The exclusion is categorical. A Medicare beneficiary with almost no income is still excluded, and someone with a high salary and a commercial plan is still eligible.
Manufacturer assistance programs invert part of that logic by asking whether you lack coverage rather than what kind you hold. Having no drug benefit at all is often the qualifying condition rather than the obstacle. Medicare beneficiaries sit in an awkward middle, which is why the Medicare site’s own pages on drug costs and available help are worth reading before assuming the answer.
Test two: what the prescription is actually for
Program scope tends to follow the label, and this is where tirzepatide gets confusing. Mounjaro is approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes. Zepbound is the separately labeled tirzepatide product carrying weight-reduction and obstructive sleep apnea indications. Same molecule, two products, two sets of program terms.
The practical consequence: a program tied to the diabetes product will look at a diabetes diagnosis on the prescription. If the prescription was written for weight management, it belongs to the other product’s rules. Confirm the current labeling on DailyMed rather than working from a secondhand summary, since indications have been added to this class repeatedly.
Nobody should misstate a diagnosis or an insurance status to clear a test. Applications are cross-checked against pharmacy claims and prescriber records, and a false statement voids the enrollment along with any product already supplied.
Test three: household income and how it is proven
Assistance programs almost always set a household income ceiling expressed as a multiple of the federal poverty level, adjusted for household size. The threshold is a number the manufacturer sets and revises, so it should be read on the program’s own current page rather than quoted from an article.
What is stable is the documentation. Programs typically want a recent federal tax return, recent pay stubs or benefit award letters, and a signed attestation of household size. Self-employment income slows applications down more than any other factor, because a tax return from fifteen months ago may not describe the household as it is today.
Test four: term, renewal, and the program year
Enrollment is time-boxed. Approvals commonly run for a defined period or through the end of a calendar year, then require re-application with fresh documentation. Copay cards carry their own limits: an annual benefit maximum, a per-fill cap, or an expiry date printed on the card itself.
People lose access here more often than they are denied at the start. Coverage that worked in November stops in January, and the reason is a rollover rather than a decision about the patient.
Where charitable foundations sit
Independent foundations answer a different question again. They fund a disease, not a brand, and they generally do accept Medicare beneficiaries, which makes them one of the few options for that group. Eligibility is income-tested against the federal poverty level, requires a diagnosis matching an open fund, and depends on the fund holding money on the day you apply. Because Mounjaro is a diabetes product, a diabetes fund is the relevant category.
Eligibility at a glance
| Program type | Who it is for | Typical disqualifier |
|---|---|---|
| Commercial copay card | Commercially insured, drug already covered | Any federal health program coverage |
| Manufacturer assistance program | Uninsured or income under the ceiling | Income above threshold, missing tax documents |
| Charitable disease fund | Insured patients, including Medicare | Fund closed, or diagnosis outside its scope |
| Direct self-pay purchase | Anyone paying without insurance | No help with cost, only a set price |
| Compounded supply | Cash payers under clinician supervision | Not FDA-approved, never covered by any program |
When no test comes back clean
Some people fail every gate at once: government coverage that blocks the card, income above the assistance ceiling, and a closed disease fund. At that point the question stops being eligibility and becomes price. The choices are the manufacturer’s own self-pay channel for the approved product, or a supervised cash-pay practice such as Hims and Hers, Ro, or formblends.com, which publish a flat monthly figure for compounded therapy prescribed through a licensed clinician. Compounded preparations are not FDA-approved and no assistance program reaches them, so that route is a purchase, not a form of help.
It is still worth pricing both, since obesity and diabetes pharmacotherapy guidance treats sustained access as part of the clinical picture rather than a billing footnote. A plan someone can actually stay on for two years usually outperforms a cheaper one that collapses at renewal.
Where price ends up deciding the matter, the published figures compare cleanly against one another. LillyDirect posts the manufacturer’s direct rate for the branded product, Henry Meds advertises a flat monthly total for compounded therapy, and HealthRX sets out the cost of Mounjaro next to what a covered patient would usually pay. Gathering two or three quotes this way describes the range far better than one number seen alone.
Frequently asked questions
Does having any insurance disqualify me from a manufacturer assistance program?
Not automatically, though many programs are written for the uninsured. Some accept patients whose plan excludes the drug entirely. The determining language sits in the program’s own eligibility terms, which change, so read the current version rather than relying on what applied during a previous enrollment year.
Why was I approved last year and denied this year?
Usually a renewal issue rather than a new judgment. Enrollments expire, income ceilings get revised, and household income changes. A plan switch also matters: moving from a commercial plan to Medicare ends copay card eligibility immediately, even mid-treatment and even when nothing else about the situation changed.
Is a diabetes diagnosis required for tirzepatide assistance?
It depends which product the program covers. Mounjaro is labeled for type 2 diabetes, so programs attached to it look for that diagnosis. Zepbound carries weight-management and sleep apnea indications and has its own terms. Check the current DailyMed label to see which product matches the prescription.
Does household income mean my income alone?
Programs generally mean total household income for everyone counted in the household size you declare, not the applicant’s earnings alone. That definition can move an applicant over the ceiling unexpectedly, and it is the item most often documented incorrectly on first submission.
